# An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients

> **NCT05356858** · PHASE2 · TERMINATED · sponsor: **Xuanwu Hospital, Beijing** · enrollment: 6 (actual)

## Conditions studied

- Neuromyelitis Optica

## Interventions

- **DRUG:** zanubrutinib

## Key facts

- **NCT ID:** NCT05356858
- **Lead sponsor:** Xuanwu Hospital, Beijing
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-05-07
- **Primary completion:** 2024-02-24
- **Final completion:** 2024-02-24
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Difficult in participant recruiting
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05356858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05356858, "An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05356858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*